MassIVE MSV000100447

Partial Public PXD073001

RHOA Controls Oncogenic B-Cell Receptor Signaling in Aggressive Lymphoma

Subscribe Comment Convert Spectra Add Reanalysis

Description

Diffuse large B cell lymphoma (DLBCL), divided into activated B-cell-like (ABC) and germinal center B-cell-like (GCB), is the most common type of aggressive lymphoma. While many studies have shown treatment response differences based on subtype, recurrently mutated proteins can further alter these responses and may require therapeutic alterations. Mutational effects in DLBCL have recently begun to be investigated, of which one mutated protein, the master cytoskeletal regulator RhoA, is here evaluated. While having been identified in previous studies, a complete investigation into the effects of this protein and its mutations in the context of DLBCL have been lacking. Through use of various methodologies, RhoA was found to play a role in the chronic active BCR signaling and NF-KB survival signal that are characteristic for the ABC DLBCL subtype. Not only was it essential in proximal BCR signaling, but additionally in the formation of the My-T-BCR super-signaling complex. Additionally, the interaction with essential surface membrane signalling proteins, and effects on internalization, emphasize the importance of this protein. Differing point mutations alter the activity of RhoA itself, along with its response to various clinically relevant inhibitors, clustering of IgM on the plasma membrane, and the actin cytoskeleton. The investigation of RhoA and its recurrent mutations are essential for deeper understanding of this malignancy. [doi:10.25345/C5RR1Q13W] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: RHOA ; Lymphoma ; DLBCL ; BCR ; DatasetType:Proteomics

Contact

Principal Investigators:
(in alphabetical order) 		Prof. Dr. Thomas Oellerich, Goethe University Clinic Frankfurt, Germany
Submitting User: BHaeup
Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

Species

Instrument

Modifications

- Dataset Reanalyses

+ Dataset History

Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.